Vol. 3 No. 3 (2026): July - September
11-21
2026-09-30
Open Access

Assessment of the association between genetic variants involved in lipid metabolism, triglyceride-rich lipoprotein levels, and mixed dyslipidemia in patients with coronary artery disease.

Malika U.Yakhyoeva
Rano B.Alieva
Aleksandr B.Shek
A.V. Bahachova
https://doi.org/10.70626/cardiouz-2026-3-00094

Received: 2026-09-15

Published: 2026-09-30

PDF (Russian)
Crossmark Crossmark

Abstract

Aim. To assess the relationship between gene variants regulating the metabolism of  LDL cholesterol (LDLR, APOB, PCSK9), TG (LPL, APOC3), and their combinations with the level of triglyceride‑rich lipoproteins in patients with coronary artery disease, to identify genetic combinations that are more common in the mixed phenotype with simultaneous elevation of TG and LDL cholesterol, and to evaluate the interaction with glucose, insulin, BMI, and waist circumference.
Materials and methods. The study included 66 patients with coronary artery disease, in whom genetic polymorphisms such as LDLR, APOB, PCSK9, LPL, APOC3 were examined using NGS. All patients were assessed for anthropometric and biochemical parameters.
Results. In a group of 66 examined patients with coronary artery disease the combination of APOC3 c.102T>C + APOB p.Ser4338Asn turned out to be the most frequent and showed a tendency to more frequent mixed DLP (simultaneous increase in TG ≥150 mg/dl (≥1.7 mmol/L) and LDL cholesterol ≥100 mg/dl (≥2.6 mmol/L), which is probably explained by the small number of observations. Waist circumference, BMI, glucose, and insulin were associated with TG more consistently than most of the common genotypic combinations studied. This supports the model of the interaction between genetic predisposition and insulin resistance and obesity.
Conclusion. The combination of APOC3 c.102T>C + APOB p.Ser4338Asn tended to be associated with mixed dyslipidemia, however, it cannot be considered as a proven genetic predictor. These findings are preliminary and require validation in larger cohorts with functional assessment of the identified variants. Further research is needed to clarify the relationship between variants of lipid metabolism genes and their combinations with the level of triglyceride‑containing lipoproteins.

Keywords

List of references

  1. Aceves-Ramírez, M., Valle, Y., Casillas-Muñoz, F., Martínez-Fernández, D. E., Parra-Reyna, B., López-Moreno, V. A., Flores-Salinas, H. E., Valdés-Alvarado, E., Muñoz-Valle, J. F., García-Garduño, T., & Padilla-Gutiérrez, J. R. (2022). Analysis of the APOB Gene and Apolipoprotein B Serum Levels in a Mexican Population with Acute Coronary Syndrome: Association with the Single Nucleotide Variants rs1469513, rs673548, rs676210, and rs1042034. Genetics research, 2022, 4901090. https://doi.org/10.1155/2022/4901090

  2. Anne-Marie K Jepsen, Anne Langsted, Anette Varbo, Lia E Bang, Pia R Kamstrup, Børge G Nordestgaard, Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease, Clinical Chemistry, Volume 62, Issue 4, 1 April 2016, Pages 593–604, https://doi.org/10.1373/clinchem.2015.253757

  3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), https://doi.org/10.1093/eurheartj/ehz455

  4. Giammanco, A., Spina, R., Cefalù, A.B. et al. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism. Curr Atheroscler Rep 25, 67–76 (2023). https://doi.org/10.1007/s11883-023-01080-8

  5. Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M. R., Tokgözoğlu, L. S., Tybjaerg-Hansen, A., … Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. European heart journal, 42(47), 4791–4806. https://doi.org/10.1093/eurheartj/ehab551

  6. Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014). Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. The New England journal of medicine, 371(1), 32–41. https://doi.org/10.1056/NEJMoa1308027

  7. Lawler, P. R., Akinkuolie, A. O., Chu, A. Y., Shah, S. H., Kraus, W. E., Craig, D., Padmanabhan, L., Glynn, R. J., Ridker, P. M., Chasman, D. I., & Mora, S. (2017). Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. Journal of the American Heart Association, 6(7), e005549. https://doi.org/10.1161/JAHA.117.005549

  8. Mansilla-Rodríguez, M. E., Sánchez-Ramos, J. L., Sánchez-Junco, A. R., Pang, J., Chan, D. C., Gutiérrez-Cortizo, E. N., Mata, P., Watts, G. F., & Romero-Jiménez, M. J. (2026). Risk factors for atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. Atherosclerosis, 415, 120650. https://doi.org/10.1016/j.atherosclerosis.2026.120650

  9. Philippa J. Talmud, Emma Hawe, Steve Martin, Michael Olivier, George J. Miller, Edward M. Rubin, Len A. Pennacchio, Steve E. Humphries, Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides, Human Molecular Genetics, Volume 11, Issue 24, 15 November 2002, Pages 3039–3046, https://doi.org/10.1093/hmg/11.24.3039

  10. Rout, M., Lerner, M., Blackett, P. R., Peyton, M. D., Stavrakis, S., Sidorov, E., & Sanghera, D. K. (2022). Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function APOC3 variants in non-Europeans. American heart journal plus: cardiology research and practice, 13, 100128. https://doi.org/10.1016/j.ahjo.2022.100128

  11. Salinas, C. A. A., & Chapman, M. J. (2020). Remnant lipoproteins: are they equal to or more atherogenic than LDL?. Current opinion in lipidology, 31(3), 132–139. https://doi.org/10.1097/MOL.0000000000000682

  12. Vanuzzo, D. The epidemiological concept of residual risk. Intern Emerg Med 6 (Suppl 1), 45 (2011). https://doi.org/10.1007/s11739-011-0669-5

  13. Waterworth, D. M., Talmud, P. J., Bujac, S. R., Fisher, R. M., Miller, G. J., & Humphries, S. E. (2000). Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arteriosclerosis, thrombosis, and vascular biology, 20(12), 2663–2669. https://doi.org/10.1161/01.atv.20.12.2663

  14. Wang, Y. E., Kirschke, C. P., Woodhouse, L. R., Bonnel, E. L., Stephensen, C. B., Bennett, B. J., Newman, J. W., Keim, N. L., & Huang, L. (2022). SNPs in apolipoproteins contribute to sex-dependent differences in blood lipids before and after a high-fat dietary challenge in healthy U.S. adults. BMC nutrition, 8(1), 95. https://doi.org/10.1186/s40795-022-00592-x

  15. World Health Organization. (2025, July 31). Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

  16. Yang, L., Zheng, B. & Gong, Y. Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. BMC Cardiovasc Disord 25, 625 (2025). https://doi.org/10.1186/s12872-025-05022-x

  17. National Center for Biotechnology Information. ClinVar; [VCV000518235.16], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000518235.16 (accessed Sept. 7, 2026).

  18. National Center for Biotechnology Information. ClinVar; [VCV000017904.19], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000017904.19 (accessed Sept. 7, 2026).

  19. National Center for Biotechnology Information. ClinVar; [VCV000128418.49], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000128418.49 (accessed Sept. 7, 2026).

  20. National Center for Biotechnology Information. ClinVar; [VCV000001550.44], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000001550.44 accessed Sept. 7, 2026).

  21. National Center for Biotechnology Information. ClinVar; [VCV000001534.21], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000001534.21 (accessed Sept. 7, 2026).

About the Authors

Malika U.Yakhyoeva
myakh39@outlook.com
Republican Specialized Scientific and Practical Medical Center of Cardiology
Rano B.Alieva
ranoalieva@mail.ru
Republican Specialized Scientific and Practical Medical Center of Cardiology
Aleksandr B.Shek
shek-999@mail.ru
Republican Specialized Scientific and Practical Medical Center of Cardiology
A.V. Bahachova
bahachovaan@gmail.com
Belarusian State University

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Assessment of the association between genetic variants involved in lipid metabolism, triglyceride-rich lipoprotein levels, and mixed dyslipidemia in patients with coronary artery disease. (M. Yakhyoeva, R. Alieva, A. Shek, & A. Bahachova, Trans.). (2026). CARDIOLOGY OF UZBEKISTAN, 3(3), 11-21. https://doi.org/10.70626/cardiouz-2026-3-00094
Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.

ISSN 3060-4850 (Print)